Compare Danaher Corporation (DHR) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs First Citizens BancShares Inc — how do they compare? Danaher Corporation trades at $200.72 (market cap $140.88B), while First Citizens BancShares Inc trades at $2,070.84 (market cap $23.65B). The key difference: Danaher Corporation is far larger — about 6× First Citizens BancShares Inc's market cap, and Danaher Corporation pays the higher dividend (0.8%). Which is the better fit depends on your goals.
| DHR | FCNCA | |
|---|---|---|
Market Cap | $140.88B | $23.65B |
Sector | Health | Sector/Thematic |
52-Week High | $242.05 | $2.20K |
52-Week Low | $161.91 | $1.64K |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
First Citizens BancShares (FCNCA) trades at $2,106.06, up 0.64% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $44.86 exceeding expectations by 13.4%. Recent developments include expansion of commercial banking capabilities and the planned retirement of the Silicon Valley Bank brand name in Q4 2026. The company maintains solid profitability with a 24.35% net income margin and 10.5% ROE, supported by $9.25B in revenue for 2025.
FCNCA presents a mixed investment case with strong fundamentals but cautious analyst sentiment. While valuation appears reasonable at 11.89 P/E and 1.18 P/B ratios, the majority of analysts (81.82%) maintain Hold ratings. Key opportunities include continued earnings momentum and strategic brand alignment, while risks involve margin pressure and credit exposure in the tech sector. The consensus price target of $2,320 suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
